Show
Sort by
-
- Journal Article
- A1
- open access
A G316A polymorphism in the ornithine decarboxylase gene promoter modulates MYCN-driven childhood neuroblastoma
-
- Journal Article
- A1
- open access
Cost-effective and robust genotyping using double-mismatch allele-specific quantitative PCR
-
- Journal Article
- A1
- open access
Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
-
- Journal Article
- A1
- open access
Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma
-
Targeted analysis of TP53 pathway SNPs in neuroblastoma patients
-
CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients
-
CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients
-
- Journal Article
- A1
- open access
CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients
-
Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma
-
Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
-
- Journal Article
- A1
- open access
Effective Alu repeat based RT-qPCR normalization in cancer cell perturbation experiments
-
- Journal Article
- A2
- open access
Selective inhibition of the p53–MDM2 interaction by nutlin drugs: a new therapeutic perspective for neuroblastoma
-
Selectieve inhibitie van de p53–MDM2 interactie door nutlin-3 als een nieuwe therapeutische strategie voor neuroblastoom
-
Pharmacological activation of p53 and gene therapy as emerging treatment options for neuroblastoma
-
Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist Nutlin-3
-
An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours
-
An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours
-
Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis
-
Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53